Dr. Christian Müller to be appointed new CFO of Carl Zeiss Meditec

Jena, Germany | 11 December 2009 | ZEISS Group

Dr. Christian Müller (42) is to be appointed as a new member of the Management Board and Chief Financial Officer of Carl Zeiss Meditec AG with effect from 15 December 2009. This was resolved by the Supervisory Board at its meeting yesterday. Dr. Müller shall succeed Bernd Hirsch, who left the company at his own request on 30 November 2009.

Müller, who has a PhD in Business Administration, began his career with the Carl Zeiss Group in 2002 in the area of auditing and risk management. Before that, Müller held a number of managerial positions within the Controlling departments of two large international corporations. From 2006 until the present day, Müller has been responsible for the Surgical Ophthalmology strategic business unit (SBU). During this time Müller has actively and successfully driven forward the expansion of this SBU and realised the integration of Acri.Tec. In his new role as a member of the Management Board and CFO of Carl Zeiss Meditec, Dr. Müller shall be responsible for the areas of finance, investor relations and IT. He shall continue, within the Management Board, to oversee the activities of the Surgical Ophthalmology SBU, the operative responsibility of which, however, will be delegated as of 1 February 2010

Dr. Markus Guthoff, Chairman of the Supervisory Board of Carl Zeiss Meditec, commented: “We are delighted to be able to appoint Dr. Christian Müller, a proven specialist and expert in our business, from within our own ranks as our new CFO. We are confident that Dr. Müller will be a very strong addition to our successful Management Board team.”

The Company shall publish its annual financial statements next Monday on 14 December 2009.

Press Contact

Jörg Nitschke
Group Spokesman
Phone: +49 7364 20-3242
joerg .nitschke @zeiss .com


The Carl Zeiss Group is a leading group of companies operating worldwide in the optical and optoelectronic industries that generates revenues totaling around EUR 2.1 billion (2008/09).

Carl Zeiss offers innovative solutions for the future-oriented markets of Medical and Research Solutions, Industrial Solutions and Lifestyle Products. The company develops and distributes surgical microscopes, diagnostic systems for ophthalmology, microscopes, lithography optics, industrial measuring technology, planetarium technology, optronic products, camera and cine lenses, and binoculars and spotting scopes. The eyeglass business is bundled in the joint venture Carl Zeiss Vision International GmbH.

The Carl Zeiss Group has approximately 13,000 employees, including more than 8,000 in Germany. The Carl Zeiss business groups hold leading positions in their markets.

Carl Zeiss AG is fully owned by the Carl Zeiss Stiftung (Carl Zeiss Foundation). Founded in 1846 in Jena, the company is headquartered in Oberkochen, Germany.


About Carl Zeiss Meditec

Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on TecDAX of the German stock exchange, is one of the world’s leading medical technology companies. The company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. It provides complete packages of solutions for the diagnosis and treatment of eye diseases - including implants and consumable materials.
The company creates innovative visualisation solutions in the field of microsurgery. Carl Zeiss Meditec's medical technology portfolio is rounded off by promising future technologies such as intraoperative radiation therapy.

In the 2008/2009 (30 September) financial year the approx. 2,100 employees generated revenue of approximately € 640 million. The head office of Carl Zeiss Meditec is in Jena, Germany. The company has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France.

Thirty-five percent of the Carl Zeiss Meditec shares are in free float. The remaining 65 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and opto-electronics industry. Carl Zeiss offers innovative solutions for the future-oriented markets "Medical and Research Solutions", "Industrial Solutions" and "Lifestyle Products". The head office of Carl Zeiss AG is in Oberkochen, Germany. In financial year 2008/2009 (balance sheet date: 30 September) the Group generated revenue of around € 2.1 billion. Carl Zeiss employs almost 13,000 staff, over 8,000 there of in Germany.

Further information at www.zeiss.com

Press Contact

Jörg Nitschke
Group Spokesman
Phone: +49 7364 20-3242
joerg .nitschke @zeiss .com

Press Photos
Dr. Christian Müller – Finanzvorstand
Further Articles

Another very successful year for the ZEISS Group

The ZEISS Group achieved significant growth across all segments despite challenging geopolitical and economic conditions.

Revenue rose by 16% to 8.8 billion euros, surpassing over 8 billion euros for the first time (prior year: 7.5 billion...

14 Dec 2022

ZEISS Academy Africa inaugurated

Strategic step to strengthen presence in South Africa and Sub-Saharan Africa.

9 Dec 2022

ZEISS microscope developers win the Deutscher Zukunftspreis 2022

The development of the ZEISS Lattice Lightsheet 7 for the gentle 3D imaging of living cells was honored with the Federal President's Award for Technology and Innovation

Today, the President of Germany, Frank-Walter Steinmeier, awarded the Deutscher Zukunftspreis 2022, The Federal Presi...

26 Oct 2022